Switch to:
Also traded in: Brazil, Chile, Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.66
CVS's Cash-to-Debt is ranked lower than
93% of the 28 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.15 vs. CVS: 0.66 )
Ranked among companies with meaningful Cash-to-Debt only.
CVS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04  Med: 0.14 Max: 5.05
Current: 0.66
0.04
5.05
Equity-to-Asset 0.28
CVS's Equity-to-Asset is ranked higher than
56% of the 27 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.38 vs. CVS: 0.28 )
Ranked among companies with meaningful Equity-to-Asset only.
CVS' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.27  Med: 0.51 Max: 0.67
Current: 0.28
0.27
0.67
Debt-to-Equity 1.72
CVS's Debt-to-Equity is ranked lower than
68% of the 19 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.59 vs. CVS: 1.72 )
Ranked among companies with meaningful Debt-to-Equity only.
CVS' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.04  Med: 0.34 Max: 1.83
Current: 1.72
0.04
1.83
Debt-to-EBITDA 7.12
CVS's Debt-to-EBITDA is ranked lower than
67% of the 18 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.82 vs. CVS: 7.12 )
Ranked among companies with meaningful Debt-to-EBITDA only.
CVS' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.14  Med: 1.39 Max: 7.12
Current: 7.12
1.14
7.12
Interest Coverage 4.39
CVS's Interest Coverage is ranked lower than
56% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 10.81 vs. CVS: 4.39 )
Ranked among companies with meaningful Interest Coverage only.
CVS' s Interest Coverage Range Over the Past 10 Years
Min: 4.39  Med: 11.4 Max: 15.55
Current: 4.39
4.39
15.55
Piotroski F-Score: 6
Altman Z-Score: 3.03
WACC vs ROIC
7.65%
12.23%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 5.11
CVS's Operating Margin % is ranked lower than
52% of the 27 Companies
in the Global Health Care Plans industry.

( Industry Median: 5.49 vs. CVS: 5.11 )
Ranked among companies with meaningful Operating Margin % only.
CVS' s Operating Margin % Range Over the Past 10 Years
Min: 5.11  Med: 6.25 Max: 6.91
Current: 5.11
5.11
6.91
Net Margin % 1.65
CVS's Net Margin % is ranked lower than
52% of the 27 Companies
in the Global Health Care Plans industry.

( Industry Median: 3.87 vs. CVS: 1.65 )
Ranked among companies with meaningful Net Margin % only.
CVS' s Net Margin % Range Over the Past 10 Years
Min: 1.65  Med: 3.5 Max: 3.76
Current: 1.65
1.65
3.76
ROE % 8.48
CVS's ROE % is ranked higher than
65% of the 26 Companies
in the Global Health Care Plans industry.

( Industry Median: 15.89 vs. CVS: 8.48 )
Ranked among companies with meaningful ROE % only.
CVS' s ROE % Range Over the Past 10 Years
Min: 8.48  Med: 11.33 Max: 17.77
Current: 8.48
8.48
17.77
ROA % 2.65
CVS's ROA % is ranked higher than
61% of the 28 Companies
in the Global Health Care Plans industry.

( Industry Median: 4.25 vs. CVS: 2.65 )
Ranked among companies with meaningful ROA % only.
CVS' s ROA % Range Over the Past 10 Years
Min: 2.65  Med: 5.97 Max: 6.99
Current: 2.65
2.65
6.99
ROC (Joel Greenblatt) % 53.57
CVS's ROC (Joel Greenblatt) % is ranked higher than
56% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 65.45 vs. CVS: 53.57 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CVS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 41.74  Med: 53.38 Max: 69.59
Current: 53.57
41.74
69.59
3-Year Revenue Growth Rate 14.80
CVS's 3-Year Revenue Growth Rate is ranked higher than
74% of the 23 Companies
in the Global Health Care Plans industry.

( Industry Median: 8.60 vs. CVS: 14.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CVS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -13.3  Med: 12.1 Max: 16.7
Current: 14.8
-13.3
16.7
3-Year EBITDA Growth Rate 9.70
CVS's 3-Year EBITDA Growth Rate is ranked lower than
55% of the 20 Companies
in the Global Health Care Plans industry.

( Industry Median: 12.70 vs. CVS: 9.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CVS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -14.8  Med: 8.8 Max: 21.8
Current: 9.7
-14.8
21.8
3-Year EPS without NRI Growth Rate 17.70
CVS's 3-Year EPS without NRI Growth Rate is ranked higher than
50% of the 16 Companies
in the Global Health Care Plans industry.

( Industry Median: 17.70 vs. CVS: 17.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CVS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -48.3  Med: 15.2 Max: 112.8
Current: 17.7
-48.3
112.8
GuruFocus has detected 6 Warning Signs with CVS Health Corp CVS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CVS's 30-Y Financials

Financials (Next Earnings Date: 2019-02-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2017

CVS Guru Trades in Q4 2017

Vanguard Health Care Fund 3,308,218 sh (New)
Bill Nygren 2,700,000 sh (New)
T Rowe Price Equity Income Fund 960,000 sh (New)
Paul Tudor Jones 28,220 sh (New)
Jim Simons 1,888,705 sh (New)
Ray Dalio 420,695 sh (New)
Robert Olstein 136,500 sh (+14.71%)
Joel Greenblatt 951,796 sh (+30.88%)
Charles Brandes 60,383 sh (+0.74%)
Richard Pzena 701,082 sh (+0.17%)
PRIMECAP Management 3,393,733 sh (+0.72%)
Steven Cohen 1,390,989 sh (+3874.25%)
Caxton Associates 14,743 sh (+287.97%)
Larry Robbins 6,821,631 sh (+398.29%)
Tom Gayner 267,000 sh (unchged)
Wallace Weitz Sold Out
Arnold Van Den Berg Sold Out
John Rogers Sold Out
Murray Stahl Sold Out
Mairs and Power Sold Out
Jerome Dodson Sold Out
Ken Fisher 233,346 sh (-10.60%)
David Dreman 10,434 sh (-58.95%)
NWQ Managers 73,212 sh (-88.00%)
John Buckingham 45,335 sh (-8.47%)
Jeremy Grantham 1,058,311 sh (-0.63%)
Jeff Auxier 69,359 sh (-0.34%)
First Pacific Advisors 61,560 sh (-85.50%)
Barrow, Hanley, Mewhinney & Strauss 15,514,373 sh (-4.28%)
Pioneer Investments 1,359,849 sh (-76.48%)
Mario Gabelli 765,246 sh (-27.07%)
Charles de Vaulx 699,939 sh (-46.59%)
» More
Q1 2018

CVS Guru Trades in Q1 2018

Andreas Halvorsen 950,311 sh (New)
Jerome Dodson 346,000 sh (New)
Philippe Laffont 5,539 sh (New)
Vanguard Health Care Fund 4,518,118 sh (+36.57%)
Bill Nygren 6,300,000 sh (+133.33%)
Ken Fisher 300,425 sh (+28.75%)
Robert Olstein 185,000 sh (+35.53%)
T Rowe Price Equity Income Fund 2,390,000 sh (+148.96%)
Richard Pzena 703,641 sh (+0.37%)
Tom Gayner 275,000 sh (+3.00%)
Jeff Auxier 69,614 sh (+0.37%)
Paul Tudor Jones 36,809 sh (+30.44%)
Jim Simons 1,919,505 sh (+1.63%)
Caxton Associates 17,245 sh (+16.97%)
Barrow, Hanley, Mewhinney & Strauss 18,102,755 sh (+16.68%)
Pioneer Investments 1,477,571 sh (+8.66%)
Larry Robbins 7,794,388 sh (+14.26%)
Ray Dalio 670,184 sh (+59.30%)
Jeremy Grantham 220,000 sh (unchged)
NWQ Managers Sold Out
Jeremy Grantham Sold Out
David Dreman 9,331 sh (-10.57%)
Joel Greenblatt 512,294 sh (-46.18%)
Charles Brandes 60,137 sh (-0.41%)
John Buckingham 43,252 sh (-4.59%)
PRIMECAP Management 3,377,691 sh (-0.47%)
Steven Cohen 814,500 sh (-41.44%)
First Pacific Advisors 52,660 sh (-14.46%)
Mario Gabelli 657,470 sh (-14.08%)
Charles de Vaulx 480,122 sh (-31.41%)
» More
Q2 2018

CVS Guru Trades in Q2 2018

Leon Cooperman 406,600 sh (New)
Ken Fisher 317,675 sh (+5.74%)
T Rowe Price Equity Income Fund 2,700,000 sh (+12.97%)
Charles Brandes 62,516 sh (+3.96%)
Richard Pzena 722,786 sh (+2.72%)
John Buckingham 44,341 sh (+2.52%)
PRIMECAP Management 3,491,231 sh (+3.36%)
Steven Cohen 822,000 sh (+0.92%)
Barrow, Hanley, Mewhinney & Strauss 18,322,542 sh (+1.21%)
Ray Dalio 698,767 sh (+4.26%)
Jerome Dodson 680,000 sh (+96.53%)
Bill Nygren 7,865,000 sh (+24.84%)
Vanguard Health Care Fund 4,518,118 sh (unchged)
Tom Gayner 275,000 sh (unchged)
First Pacific Advisors 52,660 sh (unchged)
Charles de Vaulx 480,122 sh (unchged)
Andreas Halvorsen Sold Out
Paul Tudor Jones Sold Out
Philippe Laffont Sold Out
Jim Simons Sold Out
Robert Olstein 164,000 sh (-11.35%)
Joel Greenblatt 251,945 sh (-50.82%)
Caxton Associates 6,542 sh (-62.06%)
Pioneer Investments 1,204,837 sh (-18.46%)
Larry Robbins 5,422,240 sh (-30.43%)
Mario Gabelli 610,040 sh (-7.21%)
Jeff Auxier 69,499 sh (-0.17%)
» More
Q3 2018

CVS Guru Trades in Q3 2018

Diamond Hill Capital 2,598,273 sh (New)
Philippe Laffont 2,587 sh (New)
Murray Stahl 3,114 sh (New)
Dodge & Cox 15,125,686 sh (New)
T Rowe Price Equity Income Fund 2,780,000 sh (+2.96%)
Barrow, Hanley, Mewhinney & Strauss 19,815,800 sh (+8.15%)
PRIMECAP Management 3,659,811 sh (+4.83%)
Pioneer Investments 2,709,469 sh (+124.88%)
Larry Robbins 6,614,954 sh (+22.00%)
Joel Greenblatt 532,925 sh (+111.52%)
Steven Cohen 1,953,957 sh (+137.71%)
John Buckingham 44,964 sh (+1.41%)
Jerome Dodson 680,000 sh (unchged)
Vanguard Health Care Fund 4,518,118 sh (unchged)
Tom Gayner 275,000 sh (unchged)
First Pacific Advisors Sold Out
Caxton Associates Sold Out
Ken Fisher 17,049 sh (-94.63%)
Mario Gabelli 550,317 sh (-9.79%)
Robert Olstein 128,000 sh (-21.95%)
Charles Brandes 60,282 sh (-3.57%)
Richard Pzena 719,080 sh (-0.51%)
Ray Dalio 92,216 sh (-86.80%)
Leon Cooperman 394,600 sh (-2.95%)
Jeff Auxier 69,324 sh (-0.25%)
Charles de Vaulx 472,976 sh (-1.49%)
Bill Nygren 7,300,000 sh (-7.18%)
» More
» Details

Insider Trades

Latest Guru Trades with CVS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Health Care Plans » Health Care Plans    NAICS: 621399    SIC: 8099
Compare:NYSE:ANTM, NYSE:AET, NAS:ESRX, NYSE:CI, NYSE:HUM, NYSE:CNC, NYSE:WCG, NYSE:MOH, BSP:ODPV3, BSP:QUAL3, NAS:MGLN, XPAR:GDS, NAS:HIIQ, OSTO:MCOV B, ROCO:6665, ATH:IATR, ASX:ONT, TSXV:NAC, MIL:HI, OTCPK:HFRN » details
Traded in other countries:CVSH34.Brazil, CVS.Chile, CVS.Germany, CVS.Mexico,
Headquarter Location:USA
CVS Health Corp operates in the healthcare sector. Its primary business is that of operating retail pharmacies. The company has three reportable segments namely Pharmacy Services, Retail/LTC, and Corporate.

CVS Health has vertically integrated one of the largest retail pharmacy chains in the United States with one of the largest pharmacy benefit managers. This combination makes it one of the premier healthcare firms in the U.S. The company processes approximately 1.3 billion prescriptions per year and operates more than 10,000 retail pharmacies across the U.S. The firm is now seeking to acquire Aetna, which will further extend its vertical reach and create the most integrated healthcare player in the U.S.

Guru Investment Theses on CVS Health Corp

Jerome Dodson Comments on CVS Health - Oct 31, 2018

Drugstore chain CVS Health (NYSE:CVS) increased the Fund’s return by 111 bps, as the stock went from $64.35 to $78.72 for a total return of 23.3%. Shares moved higher, after the company announced better-than-expected profits and raised earnings guidance for the year.

Investors had been concerned about the company’s policy of retaining rebates from drug companies, but management disclosed that this accounted for only 3% of its earnings, much lower than investors feared. The stock kept moving higher toward the end of the quarter, when the Department of Justice approved Cigna’s acquisition of Express Scripts, indicating that CVS’s acquisition of Aetna would probably be approved in the near future.

From Jerome Dodson (Trades, Portfolio)'s third-quarter 2018 Endeavor Fund shareholder letter.

Check out Jerome Dodson latest stock trades

Dodge & Cox Comments on CVS Health - Oct 16, 2018

During the third quarter, we initiated five new holdings in the Fund, with the largest new purchase being CVS Health. CVS Health (NYSE:CVS) operates the largest pharmacy benefit manager (PBM) and retail pharmacy chain in the United States. Concerns about pricing pressures and potential competitive threats from Amazon have lowered CVS Health’s valuation to a 20-year low. However, we believe that CVS Health’s valuation—approximately 11 times forward earnings—does not reflect the strength of its franchise. The company holds the number one position in each of its five primary business lines: PBM; specialty pharmacy; retail/mail pharmacy; Medicare prescription drug plan; and, long-term care. In addition, over the past five years, CVS Health’s shareholder-friendly management team has improved return on invested capital, generated robust free cash flow, and gained significant market share. The company acquired Caremark (a PBM) in 2006 and successfully transitioned Caremark’s prescription script volume into CVS stores. CVS Health now plans to move into managed care with its pending acquisition of Aetna (the third-largest managed care company in the United States), which is expected to close by the end of 2018. On September 30, CVS Health shares constituted 1.0% of the Fund’s portfolio.



From Dodge & Cox's third quarter 2018 shareholder commentary.



Check out Dodge & Cox latest stock trades

Bill Nygren Comments on CVS Health Corp - Jan 11, 2018

CVS Health Corporation (CVS - $73)(NYSE:CVS)
CVS is well positioned in a U.S. health care system that rewards scale, as the company owns the nation’s largest pharmacy benefit manager (PBM), the largest retail pharmacy and the largest retail clinic. Both the PBM and retail pharmacy segments are as concentrated as they have ever been, and we believe these lines of business protect existing players and pose serious challenges for new entrants. After underperforming the S&P 500 by nearly 60% over the past two years, CVS is now valued at less than 12x next year’s consensus earnings after adding back amortization of intangible assets. In our view, the market is underestimating the durability of the company’s competitive advantages across multiple end markets. Additionally, the pending acquisition of Aetna, Inc. would bring together two forward-thinking management teams and give them a broad suite of assets through which to address sector-wide trends, like the shift toward value-based care models and the increasing “consumerization” of health care.

From Bill Nygren (Trades, Portfolio)'s Oakmark Fund fourth quarter 2017 commentary.

Check out Bill Nygren latest stock trades

Weitz Funds Comments on CVS Health - Jan 26, 2017

CVS Health (NYSE:CVS) operates a nationwide network of nearly 10,000 retail pharmacies, the nation’s second largest pharmacy benefits manager (PBM) in Caremark, and sizeable specialty and long-term care pharmacy platforms. This is the fund’s second go around with CVS, having last owned it back in 2013. CVS’ stock has been under pressure for most of the last 18 months after peaking during the summer of 2015. After nearly five years of consistent market share gains, the Caremark PBM suffered several client losses over the course of 2016. In addition, CVS also announced that its retail pharmacies would no longer be part of several important networks in 2017. These lost volumes will likely result in no earnings per share growth this year. These near-term negatives drove the stock down to a price that we found attractive. While management will need to navigate several risks over the course of the next couple of years, we believe CVS’ stock price provides an attractive valuation in the mid-$70s.



  • From Weitz Investment Management's Value Fund 4th quarter 2016 commentary.


Check out Wallace Weitz latest stock trades

Top Ranked Articles about CVS Health Corp

CVS Health Introduces New Approach to Pricing of Pharmacy Benefit Management Services
CVS Pharmacy Completes Rollout of Time Delay Safes in All Kentucky Pharmacy Locations
Report: Exploring Fundamental Drivers Behind CVS Health, TransCanada, Nektar Therapeutics, LendingTree, Spectrum Pharmaceuticals, and TripAdvisor — New Horizons, Emerging Trends, and Upcoming Developments
CVS Health Observes National Influenza Vaccination Week by Encouraging Families to Get Their Flu Shot
CVS Health Completes Acquisition of Aetna, Marking Start of Transforming Consumer Health Experience
Dodge & Cox Buys CVS Health, FedEx Firm’s largest buys of 3rd quarter
Dodge & Cox was founded by Van Duyn Dodge and E. Morris Cox in 1930. The firm increased its holdings in the following stocks during the third quarter. Read more...
CVS Health to Present at the Evercore ISI HealthCONx Conference
CVS Health's MinuteClinic Receives Fifth Consecutive Accreditation From The Joint Commission
CVS Health Applauds FDA's Announcement to Restrict Flavored Tobacco Products
CVS Health Teams Up with Philadelphia Job Corps, Philadelphia Works and Philadelphia Youth Network to Open New Mock Pharmacy for Aspiring Pharmacy Technicians

Ratios

vs
industry
vs
history
PE Ratio 24.67
CVS's PE Ratio is ranked higher than
90% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 19.79 vs. CVS: 24.67 )
Ranked among companies with meaningful PE Ratio only.
CVS' s PE Ratio Range Over the Past 10 Years
Min: 9.35  Med: 16.74 Max: 27.17
Current: 24.67
9.35
27.17
Forward PE Ratio 10.03
CVS's Forward PE Ratio is ranked higher than
85% of the 13 Companies
in the Global Health Care Plans industry.

( Industry Median: 14.27 vs. CVS: 10.03 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 24.67
CVS's PE Ratio without NRI is ranked higher than
90% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 19.79 vs. CVS: 24.67 )
Ranked among companies with meaningful PE Ratio without NRI only.
CVS' s PE Ratio without NRI Range Over the Past 10 Years
Min: 9.35  Med: 16.63 Max: 27.17
Current: 24.67
9.35
27.17
Price-to-Owner-Earnings 801.08
CVS's Price-to-Owner-Earnings is ranked higher than
62% of the 16 Companies
in the Global Health Care Plans industry.

( Industry Median: 16.47 vs. CVS: 801.08 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
CVS' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 8.51  Med: 17.55 Max: 862.37
Current: 801.08
8.51
862.37
PB Ratio 2.07
CVS's PB Ratio is ranked higher than
88% of the 26 Companies
in the Global Health Care Plans industry.

( Industry Median: 3.42 vs. CVS: 2.07 )
Ranked among companies with meaningful PB Ratio only.
CVS' s PB Ratio Range Over the Past 10 Years
Min: 1.01  Med: 1.85 Max: 3.37
Current: 2.07
1.01
3.37
PS Ratio 0.40
CVS's PS Ratio is ranked higher than
80% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.73 vs. CVS: 0.40 )
Ranked among companies with meaningful PS Ratio only.
CVS' s PS Ratio Range Over the Past 10 Years
Min: 0.33  Med: 0.53 Max: 0.88
Current: 0.4
0.33
0.88
Price-to-Free-Cash-Flow 17.69
CVS's Price-to-Free-Cash-Flow is ranked higher than
72% of the 18 Companies
in the Global Health Care Plans industry.

( Industry Median: 12.78 vs. CVS: 17.69 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CVS' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.28  Med: 18.15 Max: 52.58
Current: 17.69
8.28
52.58
Price-to-Operating-Cash-Flow 12.15
CVS's Price-to-Operating-Cash-Flow is ranked higher than
75% of the 20 Companies
in the Global Health Care Plans industry.

( Industry Median: 12.15 vs. CVS: 12.15 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CVS' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.72  Med: 11.17 Max: 19.92
Current: 12.15
6.72
19.92
EV-to-EBIT 18.65
CVS's EV-to-EBIT is ranked higher than
86% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 13.89 vs. CVS: 18.65 )
Ranked among companies with meaningful EV-to-EBIT only.
CVS' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.3  Med: 10.9 Max: 18.65
Current: 18.65
6.3
18.65
EV-to-EBITDA 13.30
CVS's EV-to-EBITDA is ranked higher than
76% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 9.81 vs. CVS: 13.30 )
Ranked among companies with meaningful EV-to-EBITDA only.
CVS' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.1  Med: 8.7 Max: 13.4
Current: 13.3
5.1
13.4
EV-to-Revenue 0.63
CVS's EV-to-Revenue is ranked higher than
74% of the 27 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.01 vs. CVS: 0.63 )
Ranked among companies with meaningful EV-to-Revenue only.
CVS' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.4  Med: 0.6 Max: 1
Current: 0.63
0.4
1
PEG Ratio 2.13
CVS's PEG Ratio is ranked higher than
69% of the 13 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.35 vs. CVS: 2.13 )
Ranked among companies with meaningful PEG Ratio only.
CVS' s PEG Ratio Range Over the Past 10 Years
Min: 0.57  Med: 1.44 Max: 4.6
Current: 2.13
0.57
4.6
Shiller PE Ratio 19.75
CVS's Shiller PE Ratio is ranked higher than
92% of the 13 Companies
in the Global Health Care Plans industry.

( Industry Median: 27.53 vs. CVS: 19.75 )
Ranked among companies with meaningful Shiller PE Ratio only.
CVS' s Shiller PE Ratio Range Over the Past 10 Years
Min: 15.33  Med: 23.04 Max: 38.92
Current: 19.75
15.33
38.92
Current Ratio 2.44
CVS's Current Ratio is ranked lower than
64% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.35 vs. CVS: 2.44 )
Ranked among companies with meaningful Current Ratio only.
CVS' s Current Ratio Range Over the Past 10 Years
Min: 1.02  Med: 1.53 Max: 2.64
Current: 2.44
1.02
2.64
Quick Ratio 1.94
CVS's Quick Ratio is ranked lower than
84% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.35 vs. CVS: 1.94 )
Ranked among companies with meaningful Quick Ratio only.
CVS' s Quick Ratio Range Over the Past 10 Years
Min: 0.2  Med: 0.52 Max: 1.94
Current: 1.94
0.2
1.94
Days Inventory 34.03
CVS's Days Inventory is ranked lower than
82% of the 11 Companies
in the Global Health Care Plans industry.

( Industry Median: 7.84 vs. CVS: 34.03 )
Ranked among companies with meaningful Days Inventory only.
CVS' s Days Inventory Range Over the Past 10 Years
Min: 34.03  Med: 38.68 Max: 50.81
Current: 34.03
34.03
50.81
Days Sales Outstanding 14.09
CVS's Days Sales Outstanding is ranked higher than
55% of the 20 Companies
in the Global Health Care Plans industry.

( Industry Median: 30.58 vs. CVS: 14.09 )
Ranked among companies with meaningful Days Sales Outstanding only.
CVS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 14.09  Med: 23.74 Max: 28.31
Current: 14.09
14.09
28.31
Days Payable 20.26
CVS's Days Payable is ranked lower than
80% of the 15 Companies
in the Global Health Care Plans industry.

( Industry Median: 42.32 vs. CVS: 20.26 )
Ranked among companies with meaningful Days Payable only.
CVS' s Days Payable Range Over the Past 10 Years
Min: 16.69  Med: 19.59 Max: 21.57
Current: 20.26
16.69
21.57

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.68
CVS's Dividend Yield % is ranked higher than
84% of the 31 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.02 vs. CVS: 2.68 )
Ranked among companies with meaningful Dividend Yield % only.
CVS' s Dividend Yield % Range Over the Past 10 Years
Min: 0.55  Med: 1.26 Max: 3.29
Current: 2.68
0.55
3.29
Dividend Payout Ratio 0.66
CVS's Dividend Payout Ratio is ranked lower than
53% of the 15 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.27 vs. CVS: 0.66 )
Ranked among companies with meaningful Dividend Payout Ratio only.
CVS' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.11  Med: 0.23 Max: 0.66
Current: 0.66
0.11
0.66
3-Year Dividend Growth Rate 22.10
CVS's 3-Year Dividend Growth Rate is ranked higher than
62% of the 8 Companies
in the Global Health Care Plans industry.

( Industry Median: 19.40 vs. CVS: 22.10 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
CVS' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -33.8  Med: 8 Max: 37
Current: 22.1
-33.8
37
Forward Dividend Yield % 2.72
CVS's Forward Dividend Yield % is ranked higher than
82% of the 28 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.33 vs. CVS: 2.72 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 8.15
CVS's 5-Year Yield-on-Cost % is ranked higher than
84% of the 38 Companies
in the Global Health Care Plans industry.

( Industry Median: 4.89 vs. CVS: 8.15 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
CVS' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.67  Med: 3.83 Max: 10
Current: 8.15
1.67
10
3-Year Average Share Buyback Ratio 3.80
CVS's 3-Year Average Share Buyback Ratio is ranked higher than
90% of the 20 Companies
in the Global Health Care Plans industry.

( Industry Median: -0.50 vs. CVS: 3.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CVS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -22.9  Med: -0.4 Max: 4.7
Current: 3.8
-22.9
4.7

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.72
CVS's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
80% of the 15 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.08 vs. CVS: 0.72 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
CVS' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.55  Med: 1.34 Max: 26.44
Current: 0.72
0.55
26.44
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.49
CVS's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
78% of the 9 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.02 vs. CVS: 1.49 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
CVS' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.54  Med: 0.74 Max: 1.57
Current: 1.49
0.54
1.57
Price-to-Median-PS-Value 0.76
CVS's Price-to-Median-PS-Value is ranked higher than
83% of the 23 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.19 vs. CVS: 0.76 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CVS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.47  Med: 1.01 Max: 2.8
Current: 0.76
0.47
2.8
Price-to-Peter-Lynch-Fair-Value 4.27
CVS's Price-to-Peter-Lynch-Fair-Value is ranked higher than
64% of the 11 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.09 vs. CVS: 4.27 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
CVS' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.64  Med: 1.6 Max: 36.41
Current: 4.27
0.64
36.41
Earnings Yield (Greenblatt) % 5.36
CVS's Earnings Yield (Greenblatt) % is ranked higher than
89% of the 28 Companies
in the Global Health Care Plans industry.

( Industry Median: 6.22 vs. CVS: 5.36 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CVS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 5.36  Med: 9.2 Max: 16
Current: 5.36
5.36
16
Forward Rate of Return (Yacktman) % 13.56
CVS's Forward Rate of Return (Yacktman) % is ranked higher than
62% of the 16 Companies
in the Global Health Care Plans industry.

( Industry Median: 16.01 vs. CVS: 13.56 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
CVS' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 11.7  Med: 17.1 Max: 20.6
Current: 13.56
11.7
20.6

More Statistics

Revenue (TTM) (Mil) $188,055.00
EPS (TTM) $ 3.02
Beta1.03
Volatility34.16%
52-Week Range $60.14 - 83.88
Shares Outstanding (Mil)1,293.20

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 189,313 228,169 204,533
EBIT (Mil $) 10,720 11,458 11,521
EBITDA (Mil $) 11,626 13,856 13,176
EPS ($) 4.78 6.64 7.90
EPS without NRI ($) 4.78 6.64 7.90
EPS Growth Rate
(Future 3Y To 5Y Estimate)
8.98%
Dividends per Share ($) 1.93 2.03 2.25

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}